Literature DB >> 14673774

Effects of rhinovirus infection on the adherence of Streptococcus pneumoniae to cultured human airway epithelial cells.

Satoshi Ishizuka1, Mutsuo Yamaya, Tomoko Suzuki, Hidenori Takahashi, Shiroh Ida, Takahiko Sasaki, Daisuke Inoue, Kiyohisa Sekizawa, Hidekazu Nishimura, Hidetada Sasaki.   

Abstract

To examine the effects of rhinovirus (RV) infection on the adherence of Streptococcus pneumoniae to human tracheal epithelial cells, cells were infected with RV-14, and S. pneumoniae were added to the culture medium. The number of S. pneumoniae adhering to epithelial cells increased after RV infection. Y-24180, a specific inhibitor of the platelet-activating factor receptor (PAF-R); PAF; and the pyrrolidine derivative of dithiocarbamate, an inhibitor of transcription factor nuclear factor-kappaB (NF-kappaB), decreased the number of S. pneumoniae adhering to cells after RV-14 infection. RV-14 infection increased PAF-R expression and the activation of NF-kappaB and promoter-specific transcription factor 1. These findings suggest that RV-14 infection stimulates S. pneumoniae adhesion to airway epithelial cells via increases in PAF-Rs that are partly mediated through activation of transcription factors. Increased adherence of S. pneumoniae may be one of the reasons that pneumonia develops after RV infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14673774     DOI: 10.1086/379833

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  62 in total

1.  Influenza A virus alters pneumococcal nasal colonization and middle ear infection independently of phase variation.

Authors:  John T Wren; Lance K Blevins; Bing Pang; Lauren B King; Antonia C Perez; Kyle A Murrah; Jennifer L Reimche; Martha A Alexander-Miller; W Edward Swords
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

2.  Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species- and cell type-dependent manner.

Authors:  Vasanthi Avadhanula; Carina A Rodriguez; John P Devincenzo; Yan Wang; Richard J Webby; Glen C Ulett; Elisabeth E Adderson
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 3.  The airway epithelium: soldier in the fight against respiratory viruses.

Authors:  Marjolaine Vareille; Elisabeth Kieninger; Michael R Edwards; Nicolas Regamey
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 4.  Preventing and treating secondary bacterial infections with antiviral agents.

Authors:  Jonathan A McCullers
Journal:  Antivir Ther       Date:  2011

Review 5.  Human rhinoviruses.

Authors:  Samantha E Jacobs; Daryl M Lamson; Kirsten St George; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2013-01       Impact factor: 26.132

Review 6.  Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.

Authors:  Cameron Griffiths; Steven J Drews; David J Marchant
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 7.  Pathogenesis of rhinovirus infection.

Authors:  Joshua L Kennedy; Ronald B Turner; Thomas Braciale; Peter W Heymann; Larry Borish
Journal:  Curr Opin Virol       Date:  2012-04-27       Impact factor: 7.090

Review 8.  The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma.

Authors:  Richard Hewitt; Hugo Farne; Andrew Ritchie; Emma Luke; Sebastian L Johnston; Patrick Mallia
Journal:  Ther Adv Respir Dis       Date:  2015-11-26       Impact factor: 4.031

9.  Rhinovirus disrupts the barrier function of polarized airway epithelial cells.

Authors:  Umadevi Sajjan; Qiong Wang; Ying Zhao; Dieter C Gruenert; Marc B Hershenson
Journal:  Am J Respir Crit Care Med       Date:  2008-09-11       Impact factor: 21.405

Review 10.  Pathogen-directed therapy in acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez
Journal:  Proc Am Thorac Soc       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.